TORONTO, Sept. 22, 2014 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a
conference call on Thursday, September 25th, 2014 at 4:30 P.M. EST to
discuss Full Year Fiscal 2014 financial results. Dr. Tony Cruz,
Chairman and Chief Executive Officer of the Company, will host the
call. Transition will announce its financial results for this period in
a press release to be issued prior to the call. In order to
participate in the conference call, please call (855) 418-7483 (North
America), (678) 688-4892 (International). A replay of the conference
call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call.
Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. The Company's lead CNS drug
candidate is ELND005 for the treatment of Alzheimer's disease and Down
syndrome. Transition's lead metabolic drug candidate is TT-401 for the
treatment of type 2 diabetes and accompanying obesity. The Company's
shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto
Stock Exchange under the symbol "TTH". For additional information about
the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be
superseded by more recent information we have disclosed in later press
releases, filings with the OSC, SEC or otherwise. Except for historical
information, this press release may contain forward-looking statements,
relating to expectations, plans or prospects for Transition, including
conducting clinical trials and potential efficacy of its products.
These statements are based upon the current expectations and beliefs of
Transition's management and are subject to certain risks and
uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include factors beyond Transition's control and the risk
factors and other cautionary statements discussed in Transition's
quarterly and annual filings with the Canadian commissions.
SOURCE: Transition Therapeutics Inc.
For further information:
For further information on Transition, visit www.transitiontherapeutics.com or contact:
Dr. Tony Cruz
Chief Executive Officer
Transition Therapeutics Inc.
Phone: 416-260-7770, x.223